Kamogawa Misaki, Shuto Takashi, Matsunaga Shigeo
Department of Neurosurgery, Yokohama Rosai Hospital, Yokohama, Japan.
Surg Neurol Int. 2022 Dec 2;13:563. doi: 10.25259/SNI_802_2022. eCollection 2022.
Numerous studies have reported about good tumor control with both stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) for residual and recurrent craniopharyngiomas, but no studies have reported on the appropriate use of different types of radiation modalities. This study aimed to report the outcomes of SRS/stereotactic radiotherapy (SRT) or FSRT and compare tumor control in a single center.
From 2014 when TrueBeamTM STx with Novalis was introduced in our hospital to 2021, 21 patients underwent SRS/SRT or FSRT with gamma knife surgery (GKS) and Novalis. We have selected the radiation modalities considering mainly the distance of the optic nerve and chiasm. Imaging and clinical follow-up data were sent and reviewed.
The mean age was 52 years and there were 11 men. Of the 21 total patients, three experienced SRS (GKS, 50% isodose 12-15 Gy), five underwent SRT (GKS or Novalis, 19.5-24 Gy 3 fractions), and 13 patients underwent FSRT (Novalis, 54 Gy 30 fractions). The median follow-up was 32.6 (range 17-44) months after SRS/SRT and 34.0 (range 4-61) months after FSRT. In the SRS/SRT group, the mean tumor volume decreased from 1.103 to 0.131 cm ( < 0.01), and in the FSRT group, from 3.015 to 1.012 cm ( < 0.01). No radiation-induced optic neuropathy and other acute toxicity occurred.
Craniopharyngioma can be expected to have very good tumor control by selecting SRS/SRT or FSRT depending on the distance between the optic nerve and the tumor.
众多研究报道了立体定向放射外科(SRS)和分次立体定向放射治疗(FSRT)对残留和复发颅咽管瘤均有良好的肿瘤控制效果,但尚无研究报道不同类型放射治疗方式的合理应用情况。本研究旨在报告SRS/立体定向放射治疗(SRT)或FSRT的治疗结果,并在单一中心比较肿瘤控制情况。
自2014年我院引入配备Novalis的TrueBeamTM STx至2021年,21例患者接受了SRS/SRT或FSRT联合伽玛刀手术(GKS)及Novalis治疗。我们主要根据视神经和视交叉的距离选择放射治疗方式。发送并回顾了影像和临床随访数据。
患者平均年龄52岁,男性11例。21例患者中,3例接受SRS(GKS,50%等剂量线12 - 15 Gy),5例接受SRT(GKS或Novalis,19.5 - 24 Gy分3次),13例患者接受FSRT(Novalis,54 Gy分30次)。SRS/SRT后中位随访时间为32.6(范围17 - 44)个月,FSRT后为34.0(范围4 - 61)个月。SRS/SRT组中,平均肿瘤体积从1.103 cm³降至0.131 cm³(P < 0.01),FSRT组中,从3.015 cm³降至1.012 cm³(P < 0.01)。未发生放射性视神经病变及其他急性毒性反应。
根据视神经与肿瘤之间的距离选择SRS/SRT或FSRT,颅咽管瘤有望获得非常好的肿瘤控制效果。